

Lynn Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3275023/publications.pdf>

Version: 2024-02-01

148
papers

14,475
citations

22153

59
h-index

19749

117
g-index

149
all docs

149
docs citations

149
times ranked

10405
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. <i>Science</i> , 2010, 329, 1168-1174.	12.6	2,239
2	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	27.8	702
3	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	27.8	681
4	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	3.4	548
5	The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 ⁺ T Cell Decline and High Viral Load during Acute Infection. <i>Journal of Virology</i> , 2011, 85, 4828-4840.	3.4	441
6	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009, 15, 866-870.	30.7	390
7	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. <i>Journal of Virology</i> , 2008, 82, 11651-11668.	3.4	337
8	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. <i>Journal of Virology</i> , 2006, 80, 11776-11790.	3.4	334
9	Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2006, 80, 2515-2528.	3.4	309
10	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. <i>PLoS Medicine</i> , 2005, 2, e112.	8.4	262
11	HIV-1 Antigen-specific and -nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy. <i>Journal of Experimental Medicine</i> , 1998, 188, 233-245.	8.5	234
12	Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. <i>Journal of Virology</i> , 2005, 79, 10103-10107.	3.4	233
13	High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity. <i>Cell</i> , 2019, 179, 1636-1646.e15.	28.9	219
14	Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140. <i>Journal of Virology</i> , 2001, 75, 579-588.	3.4	216
15	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	30.7	215
16	Emergence of Drug-Resistant HIV-1 after Intrapartum Administration of Single-Dose Nevirapine Is Substantially Underestimated. <i>Journal of Infectious Diseases</i> , 2005, 192, 16-23.	4.0	214
17	Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection. <i>PLoS Pathogens</i> , 2009, 5, e1000598.	4.7	213
18	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.4	205

#	ARTICLE	IF	CITATIONS
19	Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes. <i>PLoS Pathogens</i> , 2013, 9, e1003738.	4.7	190
20	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	8.4	188
21	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study. <i>PLoS ONE</i> , 2008, 3, e1954.	2.5	175
22	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. <i>Journal of Virology</i> , 2009, 83, 8925-8937.	3.4	170
23	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , 2012, 209, 1469-1479.	8.5	156
24	The Antibody Response against HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007039-a007039.	6.2	152
25	Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop. <i>Journal of Virology</i> , 2011, 85, 3128-3141.	3.4	151
26	The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection. <i>Journal of Virology</i> , 2008, 82, 1860-1869.	3.4	142
27	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	11.0	137
28	A Reliable Phenotype Predictor for Human Immunodeficiency Virus Type 1 Subtype C Based on Envelope V3 Sequences. <i>Journal of Virology</i> , 2006, 80, 4698-4704.	3.4	124
29	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. <i>Science Translational Medicine</i> , 2016, 8, 358ra125.	12.4	121
30	Incidence of HIV-1 Dual Infection and Its Association with Increased Viral Load Set Point in a Cohort of HIV-1 Subtype C-Infected Female Sex Workers. <i>Journal of Infectious Diseases</i> , 2004, 190, 1355-1359.	4.0	119
31	Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 133-144.	1.1	113
32	Regional Clustering of Shared Neutralization Determinants on Primary Isolates of Clade C Human Immunodeficiency Virus Type 1 from South Africa. <i>Journal of Virology</i> , 2002, 76, 2233-2244.	3.4	111
33	HIV broadly neutralizing antibody targets. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 135-143.	3.8	110
34	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report. <i>PLoS ONE</i> , 2009, 4, e4505.	2.5	109
35	Viremia, Resuppression, and Time to Resistance in Human Immunodeficiency Virus (HIV) Subtype C during First-Line Antiretroviral Therapy in South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 1928-1935.	5.8	107
36	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	11.0	105

#	ARTICLE	IF	CITATIONS
37	Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. <i>Aids</i> , 2010, 24, 1679-1687.	2.2	100
38	Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection. <i>Cell Host and Microbe</i> , 2018, 23, 845-854.e6.	11.0	100
39	Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. <i>Virology</i> , 2010, 402, 187-196.	2.4	95
40	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. <i>Journal of Virology</i> , 2009, 83, 11265-11274.	3.4	93
41	Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. <i>Aids</i> , 2006, 20, 995-1002.	2.2	87
42	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. <i>Virology</i> , 2009, 387, 414-426.	2.4	86
43	Ability To Develop Broadly Neutralizing HIV-1 Antibodies Is Not Restricted by the Germline Ig Gene Repertoire. <i>Journal of Immunology</i> , 2015, 194, 4371-4378.	0.8	85
44	Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. <i>PLoS ONE</i> , 2011, 6, e17518.	2.5	84
45	Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. <i>Aids</i> , 2008, 22, 1333-1343.	2.2	83
46	Selection and Persistence of Viral Resistance in HIV-Infected Children After Exposure to Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 148-153.	2.1	79
47	HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. <i>Aids</i> , 2006, 20, 643-651.	2.2	78
48	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.	3.2	78
49	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. <i>Virology</i> , 2009, 385, 505-520.	2.4	78
50	Virological features associated with the development of broadly neutralizing antibodies to HIV-1. <i>Trends in Microbiology</i> , 2015, 23, 204-211.	7.7	77
51	Reuse of Nevirapine in Exposed HIV-Infected Children After Protease Inhibitor-Based Viral Suppression. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1082.	7.4	75
52	Persistent Minority K103N Mutations among Women Exposed to Single-Dose Nevirapine and Virologic Response to Nonnucleoside Reverse-Transcriptase Inhibitor-Based Therapy. <i>Clinical Infectious Diseases</i> , 2009, 48, 462-472.	5.8	74
53	Insensitivity of Paediatric HIV-1 Subtype C Viruses to Broadly Neutralising Monoclonal Antibodies Raised against Subtype B. <i>PLoS Medicine</i> , 2006, 3, e255.	8.4	72
54	Does Tuberculosis Increase HIV Load?. <i>Journal of Infectious Diseases</i> , 2004, 190, 1677-1684.	4.0	71

#	ARTICLE	IF	CITATIONS
55	Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. <i>BMC Public Health</i> , 2011, 11, 88.	2.9	69
56	Human Immunodeficiency Virus ¹ RNA Levels and CD4 Lymphocyte Counts, during Treatment for Active Tuberculosis, in South African Patients. <i>Journal of Infectious Diseases</i> , 2003, 187, 1967-1971.	4.0	68
57	Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma. <i>Journal of Virology</i> , 2009, 83, 1240-1259.	3.4	67
58	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	11.0	66
59	Human Immunodeficiency Virus-Specific Gamma Interferon Enzyme-Linked Immunospot Assay Responses Targeting Specific Regions of the Proteome during Primary Subtype C Infection Are Poor Predictors of the Course of Viremia and Set Point. <i>Journal of Virology</i> , 2009, 83, 470-478.	3.4	63
60	International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II. <i>PLoS ONE</i> , 2012, 7, e36438.	2.5	63
61	Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. <i>Virology</i> , 2006, 356, 95-105.	2.4	59
62	Specificity of the autologous neutralizing antibody response. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 358-363.	3.8	59
63	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013, 18, 125-131.	2.3	58
64	HIV Type 1 Subtype C Drug Resistance among Pediatric and Adult South African Patients Failing Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1449-1454.	1.1	54
65	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. <i>Journal of Virology</i> , 2011, 85, 7719-7729.	3.4	54
66	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	6.4	53
67	Characterization of Full-Length HIV Type 1 Subtype C Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1527-1531.	1.1	52
68	Genotypic and Phenotypic Characterization of Viral Isolates from HIV-1 Subtype C-Infected Children with Slow and Rapid Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 458-465.	1.1	51
69	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51
70	Use of a novel washing method combining multiple density gradients and trypsin for removing human immunodeficiency virus-1 and hepatitis C virus from semen. <i>Fertility and Sterility</i> , 2005, 84, 1001-1010.	1.0	50
71	Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nucleoside Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 960-971.	3.2	48
72	Viral Suppression Following Switch to Second-line Antiretroviral Therapy: Associations With Nucleoside Reverse Transcriptase Inhibitor Resistance and Subtherapeutic Drug Concentrations Prior to Switch. <i>Journal of Infectious Diseases</i> , 2014, 209, 711-720.	4.0	47

#	ARTICLE	IF	CITATIONS
73	Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 803-809.	9.1	47
74	HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes. <i>Journal of Virology</i> , 2018, 92, .	3.4	47
75	Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. <i>Virology</i> , 2007, 368, 172-181.	2.4	45
76	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	6.4	45
77	Use of alternate coreceptors on primary cells by two HIV-1 isolates. <i>Virology</i> , 2005, 339, 136-144.	2.4	44
78	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet</i> , The, 2020, 395, 384-388.	13.7	44
79	N-Linked Glycan Modifications in gp120 of Human Immunodeficiency Virus Type 1 Subtype C Render Partial Sensitivity to 2G12 Antibody Neutralization. <i>Journal of Virology</i> , 2007, 81, 10769-10776.	3.4	42
80	Meningitis in a community with a high prevalence of tuberculosis and HIV infection. <i>Journal of the Neurological Sciences</i> , 1999, 162, 20-26.	0.6	41
81	Full-Length Genome Analysis of HIV-1 Subtype C Utilizing CXCR4 and Intersubtype Recombinants Isolated in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 879-886.	1.1	39
82	HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. <i>Aids</i> , 2011, 25, 1461-1469.	2.2	39
83	HIV-1 Subtype C Reverse Transcriptase Sequences from Drug-Naive Pregnant Women in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 605-610.	1.1	38
84	Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study. <i>Journal of Virology</i> , 2008, 82, 11476-11479.	3.4	38
85	Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype C. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 9-15.	2.1	38
86	4E10-Resistant Variants in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Individual with an Anti-Membrane-Proximal External Region-Neutralizing Antibody Response. <i>Journal of Virology</i> , 2008, 82, 2367-2375.	3.4	37
87	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	6.1	34
88	A Model of Directional Selection Applied to the Evolution of Drug Resistance in HIV-1. <i>Molecular Biology and Evolution</i> , 2007, 24, 1025-1031.	8.9	33
89	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	4.7	33
90	Resistance Mutational Analysis of HIV Type 1 Subtype C among Rural South African Drug-Naive Patients Prior to Large-Scale Availability of Antiretrovirals. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 1306-1312.	1.1	32

#	ARTICLE	IF	CITATIONS
91	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. <i>Journal of Immunological Methods</i> , 2018, 463, 71-83.	1.4	32
92	HIV-1 Subtype A, D, G, AG and Unclassified Sequences Identified in South Africa. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 681-683.	1.1	30
93	Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. <i>Journal of AIDS & Clinical Research</i> , 2011, 02, .	0.5	30
94	Transmission Rates in Consecutive Pregnancies Exposed to Single-Dose Nevirapine in Soweto, South Africa and Abidjan, CÔte d'Ivoire. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 206-209.	2.1	29
95	Prospects for passive immunity to prevent HIV infection. <i>PLoS Medicine</i> , 2017, 14, e1002436.	8.4	29
96	Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. <i>Aids</i> , 2003, 17, 1698-1700.	2.2	27
97	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , 2020, 17, e1003038.	8.4	27
98	Detection of Low-Level K65R Variants in Nucleoside Reverse Transcriptase Inhibitor-“Naive Chronic and Acute HIV-1 Subtype C Infections. <i>Journal of Infectious Diseases</i> , 2011, 203, 798-802.	4.0	26
99	Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage. <i>PLoS ONE</i> , 2015, 10, e0131906.	2.5	26
100	Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 316-321.	1.1	25
101	Characterization of Human Immunodeficiency Virus Type 1 from a Previously Unexplored Region of South Africa with a High HIV Prevalence. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 103-109.	1.1	24
102	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 285-291.	1.1	24
103	V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity. <i>Cell Reports</i> , 2018, 25, 3123-3135.e6.	6.4	23
104	Polymorphisms in Nef Associated with Different Clinical Outcomes in HIV Type 1 Subtype C-Infected Children. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 204-215.	1.1	21
105	Identification of HIV Type 1 Intersubtype Recombinants in South Africa Using env and gag Heteroduplex Mobility Assays. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 493-497.	1.1	20
106	Conserved Domains of Subtype C Nef from South African HIV Type 1-Infected Individuals Include Cytotoxic T Lymphocyte Epitope-Rich Regions. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1681-1687.	1.1	20
107	Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 169-176.	3.8	20
108	South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on λ 4127 for replication. <i>Retrovirology</i> , 2015, 12, 54.	2.0	19

#	ARTICLE	IF	CITATIONS
109	Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance. <i>Aids</i> , 2009, 23, 809-816.	2.2	17
110	Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2248-2256.	3.2	17
111	Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3056-3064.	3.2	16
112	Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. <i>Journal of Virological Methods</i> , 2010, 164, 122-126.	2.1	16
113	Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope. <i>Journal of Virology</i> , 2020, 94, .	3.4	15
114	Predicted genotypic resistance to the novel entry inhibitor, BMS-378806, among HIV-1 isolates of subtypes A to G. <i>Aids</i> , 2004, 18, 2327-2330.	2.2	14
115	In Vitro Generation of HIV Type 1 Subtype C Isolates Resistant to Enfuvirtide. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 776-783.	1.1	14
116	Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. <i>Virology</i> , 2009, 393, 56-67.	2.4	14
117	Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 776-782.	1.1	14
118	Population-Based Surveillance of HIV Drug Resistance Emerging on Treatment and Associated Factors at Sentinel Antiretroviral Therapy Sites in Namibia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 463-471.	2.1	14
119	Silencing of HIV-1 Subtype C Primary Isolates by Expressed Small Hairpin RNAs Targeted togag. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 401-410.	1.1	13
120	Serum glycan-binding IgG antibodies in HIV-1 infection and during the development of broadly neutralizing responses. <i>Aids</i> , 2017, 31, 2199-2209.	2.2	13
121	Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies. <i>Journal of Virology</i> , 2019, 93, .	3.4	13
122	Characterization of anti-HIV-1 neutralizing and binding antibodies in chronic HIV-1 subtype C infection. <i>Virology</i> , 2012, 433, 410-420.	2.4	12
123	Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. <i>Journal of Virological Methods</i> , 2005, 125, 99-109.	2.1	10
124	HIV Disease Progression in Seroconvertors from the CAPRISA 004 Tenofovir Gel Pre-exposure Prophylaxis Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 68, 55-61.	2.1	10
125	Neutralizing Antibody Responses to HIV-1 Infection. <i>IUBMB Life</i> , 2002, 53, 197-199.	3.4	9
126	Development of Phenotypic HIV-1 Drug Resistance After Exposure to Single-Dose Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 538-543.	2.1	9

#	ARTICLE	IF	CITATIONS
127	mRNA vaccines offer hope for HIV. <i>Nature Medicine</i> , 2021, 27, 2082-2084.	30.7	9
128	Randomized Trial of Time-Limited Interruptions of Protease Inhibitor-Based Antiretroviral Therapy (ART) vs. Continuous Therapy for HIV-1 Infection. <i>PLoS ONE</i> , 2011, 6, e21450.	2.5	8
129	The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. <i>Journal of Virological Methods</i> , 2015, 223, 30-32.	2.1	8
130	Differences in HIV Type 1 Neutralization Breadth in 2 Geographically Distinct Cohorts in Africa. <i>Journal of Infectious Diseases</i> , 2015, 211, 1461-1466.	4.0	7
131	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. <i>Nature Communications</i> , 2022, 13, 903.	12.8	7
132	Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAbs lineage. <i>PLoS Pathogens</i> , 2019, 15, e1008005.	4.7	6
133	High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. <i>Journal of Medical Virology</i> , 2006, 78, 1262-1268.	5.0	5
134	Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. <i>Journal of Virological Methods</i> , 2014, 207, 182-187.	2.1	5
135	The importance of doing HIV research in developing countries. <i>Nature Medicine</i> , 1998, 4, 1228-1229.	30.7	3
136	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. <i>PLoS ONE</i> , 2020, 15, e0234937.	2.5	3
137	Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. <i>Viruses</i> , 2021, 13, 1296.	3.3	3
138	Viral Escape Pathways from Broadly Neutralising Antibodies Targeting the HIV Envelope Cleavage Site Enhance MPER Mediated Neutralisation. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A20-A21.	1.1	1
139	The Sequence of the $\hat{I}\pm 4\hat{I}^{27}$ -binding Motif on Gp120 of Transmitted/Founder Viruses Contributes to the Dependence on the Integrin for HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A56-A56.	1.1	1
140	Engineered HIV antibody passes muster. <i>Lancet HIV</i> , 2019, 6, e641-e642.	4.7	1
141	Infection of Chinese Rhesus Monkeys with a Subtype C SHIV Resulted in Attenuated In Vivo Viral Replication Despite Successful Animal-to-Animal Serial Passages. <i>Viruses</i> , 2021, 13, 397.	3.3	1
142	AIDS dissidents aren't victims " but the people their ideas kill will be. <i>Nature</i> , 2000, 405, 273-273.	27.8	0
143	Viral structure, replication, tropism, pathogenesis and natural history. , 0, , 87-96.		0
144	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0

#	ARTICLE	IF	CITATIONS
145	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
146	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
147	HIV-1 re-suppression on a first-line regimen despite the presence of phenotypic drug resistance. , 2020, 15, e0234937.		0
148	HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies. Journal of Virology, 0, , .	3.4	0